GLG. Llort

G. Llort

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


G. Llort has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IDENTIFICATION OF CLINICAL, GENETIC AND ENDOSCOPIC PREDICTORS OF INCIDENT COLORECTAL CANCER IN LYNCH SYNDROME UNDER COLONOSCOPY SCREENING

    by A Sanchez Garcia, M Navarro, L Moreno, T Ocaña, F Rodríguez-Moranta, L Rodríguez-Alonso, A Soriano, T Ramon Y Cajal, G Llort, C Yagüe, et al.

    Aims: Lynch syndrome (LS) families have a high risk of colorectal cancer (CRC) development. Colonoscopy every < 3 years decreases CRC incidence and mortality. However, recent studies show that up to 40% develop CRC during colonoscopy follow-up. Our aim is to assess the clinic-pathological, genetic and endoscopy quality measures that are predictors of CRC during colonoscopy surveillance in LS carriers. Methods: Multicenter nation-wide study with retrospective collection of prospectively observed data from high-risk clinics. Demographic, genetic, family and personal cancer history, and surveillance protocols data were collected between 2015 – 2017. First prospectively colonoscopy planned as LS screening was considered as date of inclusion. Cumulative incidence of the first CRC diagnosed under screening was calculated by gene/gender. CRCs diagnosed prior or within the first colonoscopy (prevalent cancers) were excluded. Additionally, endoscopic factors of CRC were analyzed. Results: We included 1,108 LS cases, 631 (56.9%) female, median age of 53 years (SD: 15.4), and a median follow-up of 58.4 months (SD: 53.7). Distribution per gene was: 449 (40.4%) MLH1, 372 (33.6%) MSH2, 197 (17.9%) MSH6 and 23 (2.1%) EPCAM. The prevalence of CRC was 38.4% (426). Healthy carriers (649) with proven endoscopic surveillance were selected (n = 539) observing 17/539 (3.15%) incident CRC during endoscopic screening: 7/192 MLH1, 9/192 MSH2, 1/113 MSH6, 0/37 PMS2 and 0/5 EPCAM. Inadequate endoscopic follow-up was present in 7/17 incident CRC including longer than 3 years interval (n = 4) or inadequate bowel-cleansing (n = 3). Cumulative CRC incidence at 70 years under endoscopic follow-up was calculate per gen: 13.8% (95% CI: 5.9 – 10.4%) for MLH1; 18.5% (95% CI: 8.8 – 36.4%) for MSH2 and 1% (95% CI: 0.15 – 7.1%) for MSH6; and gender: 16.7% (95% CI: 8 – 21.1%) males and 8.7% (95% CI: 3.9 – 19%) females. Conclusions: A preliminary analysis of this large multicenter study, reveals that cumulative incidence of a first CRC under screening colonoscopy is lower than previously published. Our results suggest that colonoscopy is highly effective for CRC prevention in LS, and that high quality endoscopic standards are key for its effectiveness.

  • Open Access

    SEOM clinical guidelines in Hereditary Breast and ovarian cancer

    by On behalf of the SEOM Hereditary Cancer Working Group, G. Llort, I. Chirivella, R. Morales, R. Serrano, A. Beatriz Sanchez, A. Teulé, E. Lastra, J. Brunet, J. Balmaña, et al.

    Approximately, 7 % of all breast cancers (BC) and 11–15 % of ovarian cancers (OC) are associated with inherited predisposition, mainly related to germline mutations in high penetrance BRCA1/2 genes. Clinical criteria for genetic testing are based on personal and family history to estimate a minimum 10 % detection rate. Selection criteria are evolving according to new advances in this field and the clinical utility of genetic testing. Multiplex panel testing carries its own challenges and we recommend inclusion of genes with clinical utility. We recommend screening with annual mammography from age 30 and breast MRI from age 25 for BRCA1 and BRCA2 mutation carriers. Bilateral salpingo-oophorectomy should be offered to women with a BRCA1 or BRCA2 mutation, between 35 and 40 years and after completion of childbearing, or individualise based on the earliest age of ovarian cancer diagnosed in the family. Bilateral risk-reducing mastectomy is an option for healthy BRCA1 and BRCA2 mutation carriers, as well as contralateral mastectomy for young patients with a prior BC diagnosis. BRCA genetic testing in patients with BC and OC may influence their locoregional and systemic treatment.